104,846 Shares in Repligen Corporation $RGEN Purchased by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P purchased a new stake in shares of Repligen Corporation (NASDAQ:RGEN) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 104,846 shares of the biotechnology company’s stock, valued at approximately $13,041,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Twin Tree Management LP purchased a new position in shares of Repligen during the first quarter valued at approximately $29,000. Hantz Financial Services Inc. boosted its holdings in Repligen by 2,663.6% in the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 293 shares in the last quarter. Center for Financial Planning Inc. increased its position in Repligen by 34.2% during the 2nd quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 126 shares during the period. AlphaQuest LLC purchased a new position in Repligen during the 2nd quarter valued at $104,000. Finally, Hilltop National Bank bought a new position in Repligen in the 2nd quarter worth $147,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Stock Down 0.0%

NASDAQ:RGEN opened at $171.11 on Monday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. The firm has a market cap of $9.63 billion, a P/E ratio of 8,559.78, a P/E/G ratio of 3.32 and a beta of 1.15. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52. The firm has a 50-day simple moving average of $149.72 and a two-hundred day simple moving average of $131.80.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. Repligen had a net margin of 0.25% and a return on equity of 4.70%. The firm had revenue of $188.81 million for the quarter, compared to analysts’ expectations of $181.23 million. During the same quarter in the prior year, the company posted $0.43 earnings per share. The business’s revenue for the quarter was up 21.9% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Analysts predict that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Repligen from a “buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Canaccord Genuity Group lifted their price objective on Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a research report on Wednesday, October 29th. HSBC assumed coverage on Repligen in a report on Wednesday, October 1st. They set a “buy” rating and a $150.00 target price on the stock. Weiss Ratings restated a “sell (d+)” rating on shares of Repligen in a research note on Tuesday, November 25th. Finally, Barclays upped their price target on Repligen from $160.00 to $175.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $173.85.

Insiders Place Their Bets

In related news, Director Anthony Hunt sold 20,000 shares of the stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $154.61, for a total transaction of $3,092,200.00. Following the sale, the director directly owned 80,743 shares of the company’s stock, valued at $12,483,675.23. This trade represents a 19.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO James Bylund sold 2,191 shares of Repligen stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total value of $331,301.11. Following the completion of the sale, the chief operating officer owned 21,520 shares of the company’s stock, valued at $3,254,039.20. The trade was a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 49,382 shares of company stock valued at $7,676,802. Corporate insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.